SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

NanoLogix, Inc. (NNLX)

NNLX RSS Feed
Add NNLX Price Alert      Hide Sticky   Hide Intro
Moderator: Emerald Isle
Search This Board:
Last Post: 11/11/2016 5:06:21 PM - Followers: 131 - Board type: Free - Posts Today: 0
 
ABOUT NANOLOGIX

Mission
Nanologix is a biotechnology company focused on sale of Petri plates packaged in an exclusive licensed Flatpack and the N-Assay rapid detection technology for bacteria, mold, and spores. 
NanoLogix technology is used to test for bacteria and other microorganisms and in some cases, dependent upon the technology used, provide for early detection of bacteria and other microorganisms present in infectious and noninfectious human diseases, the environment, industrial and manufacturing settings, veterinary medicine, and research and testing laboratories. 
 
History
NanoLogix began 26 years ago under the name Infectech. From its founding through 2007 the Company had been issued patents that were in some cases practically, and in other cases theoretically, applicable in the areas of applied microbiology, soil microbiology, medical diagnostics, microbial physiology, pharmacology, pharmaco-kinetics, and determination of antibiotic sensitivity.
In 2007, with a management change, the focus of the company changed from Research and Development to exploring how to capitalize on the company's existing intellectual property. It became obvious that the patents of the past possessed little monetary value for the future and that realization resulted in a further change in direction seeking to focus on practicality in research and a focus on a long term future return for the company and its shareholders. The period from 2007 through 2011 resulted in the abandonment of any focus on the production of hydrogen through bacteria degradation of organic waste utilizing what was referred to as a "bioreactor". The reason for the abandonment of the technology was the discovery of a lack of evidence for any economic potential for the technology. A similar discovery led to the practical abandonment of the NanoLogix BNC (BioNanoChannel) technology. While potentially a novel approach to diagnostics, major-lab third-party tests and a subsequent economic analysis demonstrated that under no conditions could the cost of both the antibody coating and specialized glass microchannel disc contained in the apparatus be reduced to a level to enable effective marketing.   Over the following year, NanoLogix went through a transition to production of  FlatPack™ Petri plates and BNP™ diagnostic test kits. Sales of both began in Q3 2012.    
 
.

NanoLogix' rapid diagnostic technology is the N-Assay modified ELISA diagnostic.
 

Nanologix Technology

NanoLogix N-Assay technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), Nanologix technology does not require large investments in equipment or personnel training.
Rapid diagnostics allow researchers in the lab to test for potentially pathogenic agents faster and develop effective countermeasures more rapidly and economically. This quality presents exciting opportunities in the pharmaceutical design process, and furnishes the follwing as benefits:

Can begin more effective drug treatment when an infectious disease is identified at an early stage. The spread of infectious disease may be reduced by earlier intervention. 
In combat theaters and homeland security settings, the presence of specific pathogens can be detected closer to the epicenter of release. Site decontamination teams can identify surface samples closer to real time, potentially aiding the field process. 
Industrial production - of food, beverage, drugs, or beauty products - can be paralyzed by microbial contamination.  The ripple effect may include expensive recalls, bad publicity, and government mandated "microbiology holds" that delay the replacement of product.  Rapid diagnostics can help minimize the impact by limiting the spread of spoiled product.
 
 
 
Market
The volume of Petri dishes used for traditional tests is millions per day worldwide.
According to Industrial Microbiology Market Review, worldwide industrial microbiology testing is undergoing tremendous growth. The same growth pattern is anticipated in the medical microbiological diagnostics market.
NanoLogix's potential customers are numerous and varied. They include microbiological laboratories in the industrial, medical, environmental, governmental (federal, state and local) sectors, research and development facilities, and educational institutions. 
 
R&D
NanoLogix's research and development continues on other diagnostic technology with variants in the N-Assay currently being developed for one of the world's largest Medical Device companies.
 
      http://dx.doi.org/10.1155/2016/5293034   Infectious Diseases in Obstetrics and Gynecology Volume 2016 (2016), Article ID 5293034, 7 pages 
Research Article

Development of a Novel Test for Simultaneous Bacterial Identification and Antibiotic Susceptibility

Jonathan Faro,1 Malika Mitchell,2 Yuh-Jue Chen,2 Sarah Kamal,2 Gerald Riddle,1 and Sebastian Faro1

1The Woman’s Hospital of Texas, 7400 Fannin Suite 930, Houston, TX 77054, USA
2The University of Texas Health Science Center at Houston, Medical College, Houston, TX 77054, USA

Received 13 May 2016; Accepted 10 August 2016

Academic Editor: Bryan Larsen

Copyright © 2016 Jonathan Faro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Elucidation of a pathogen’s antimicrobial susceptibility requires subculture after the organism is first isolated. This takes several days, requiring patients to be treated with broad-spectrum antibiotics. This approach contributes to the development of bacterial resistance. Methods. Microtiter wells were coated with a polyclonal antibody targeting the pathogen of interest. Bacterial suspensions were added in the presence/absence of selected antibiotics. After washing, captured bacteria were detected. Findings. Group B streptococcus (GBS), Enterococcus faecalis, and Neisseria gonorrhoeae were each detected at 105 bacteria/mL following a 20-minute incubation period. Susceptibility to select antibiotics was discernable following a 6-hour incubation period (GBS and Enterococcus). Sensitivity was increased to 10−2 bacteria/mL for GBS, 10−1 bacteria/mL for E. faecalis, and 101 bacteria/mL for N. gonorrhoeae following 18–24-hour culture. Conclusion. This novel assay allows for the highly sensitive and specific identification of a pathogen and simultaneous determination of its antimicrobial susceptibility in a reduced time.





 
 
· 
*********************
PATENTS
*********************

The patent information link:
http://www.nanologix.com/index-4.html



*********************
SHARE STRUCTURE
*********************

 

Estimated Market Cap

  • $8,410,892 as of December 31, 2015

 

Outstanding Shares

         As of 31 December 2015, the company has 140,181,530 shares outstanding. Outstanding on 12/31/14 were 139,531,530         shares.

         Authorized Shares         200,000,000 as of Dec 31, 2015
 

Number of Share Holders of Record

  • 2,000+/- shareholders as of end of 2015.

        Float of 109,522,269 shares as of Dec 31, 2015



*************************
PRESS RELEASES
*************************

http://www.nanologix.com/news.htm


*******************
NNLX CHARTS
*******************

Price Quote:
http://www.investorshub.com/boards/quotes.asp?ticker=NNLX


( 1 month daily, 3 month daily, 1 year weekly)




________________________________________________________________________________________________________________________________

 

CONTACT

Corporate Headquarters

NanoLogix, Inc.

843 North Main Street
Hubbard, OH 44425 USA
330-534-0800 main line
330-534-0826 fax

E-mail: info@nanologix.com

Web site questions:

E-mail: webmaster@nanologix.com



ABOUT NANOLOGIX:
 

NANOLOGIX IS A BIOTECHNOLOGY COMPANY specializing in rapid diagnostics tools for biodefense, medical, environmental, and industrial uses.

The primary focus of NanoLogix is rapid detection of bacteria and other microorganisms.

 

Uses for NanoLogix's very-rapid diagnostics include biodefense, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing. Rapid detection of microorganisms is an annual multi-billion dollar market.

NanoLogix has been issued 33 patents in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.. 



 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NNLX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#8230  Sticky Note EVERYONE get your posts back on-topic. The IH Geek [Dave] 11/21/13 03:54:06 PM
#9218   Thank you. EOM Sleepin_Easy 11/11/16 05:06:21 PM
#9217   To get the emails, sign in at www.nanologix.com lockshed 11/11/16 05:02:18 PM
#9216   Thanks, kphone. How does one gets signed up Sleepin_Easy 11/11/16 04:43:51 PM
#9215   EU & Hong Kong FlatPack Patent Approval Notice Received kphone2004 11/11/16 10:00:44 AM
#9214   Thank you, EI. EOM Sleepin_Easy 11/09/16 04:33:34 PM
#9213   New Update From The Company Emerald Isle 11/09/16 03:37:06 AM
#9212   Totally agreed. However, since they do conduct dhw 11/03/16 01:36:14 PM
#9211   A new website will be interesting and not yman 11/03/16 01:29:52 PM
#9210   Sure. Depends on complexity of site, on how dhw 11/03/16 12:35:28 PM
#9209   Would you care to explain to me why Sleepin_Easy 11/03/16 12:21:45 PM
#9208   It is totally normal. dhw 11/03/16 12:17:52 PM
#9207   I e-mailed NanoLogix this morning about the new Sleepin_Easy 11/03/16 11:59:31 AM
#9206   Yman, Given the update this afternoon and the furnished Emerald Isle 11/03/16 11:13:25 AM
#9205   Does anyone know what the plans are for yman 11/02/16 02:35:52 PM
#9204   Who remembers that run up over a dollar ttboy 11/02/16 08:29:30 AM
#9203   Thank you, EI. ttboy 11/02/16 08:21:25 AM
#9202   Emerald, Yes great news about the conference, conference paper gosox12 11/01/16 10:54:11 PM
#9201   Truth be told without Brett NNLX would have Threes 11/01/16 10:15:31 PM
#9200   I am back to even on my initial Muggo11 11/01/16 10:03:37 PM
#9199   Abig, I'm just home from celebrating with my mates Emerald Isle 11/01/16 08:54:03 PM
#9198   You know what would have been good with Abig 11/01/16 07:01:33 PM
#9197   TT, Yes, there was a press release: Emerald Isle 11/01/16 03:33:18 PM
#9196   EI, Was there a PR today (11/1), or ttboy 11/01/16 01:51:53 PM
#9195   Great Press Release This Morning! Emerald Isle 11/01/16 07:49:04 AM
#9194   Nice! lockshed 10/30/16 08:48:56 PM
#9193   Research Paper on N-Assay is formally published in Emerald Isle 10/30/16 03:52:04 PM
#9192   Longpicker, Thanks so much for this great update. By gosox12 10/29/16 06:37:50 PM
#9191   Ok I just got the word from the conference. Longpicker 10/29/16 01:55:34 PM
#9190   My hope is a buyout of 10 dollars drugmanrx 10/28/16 12:39:03 PM
#9189   JJBittings 10/28/16 11:57:44 AM
#9188   Impressive movement in the last few days. Anyone JJBittings 10/28/16 11:56:51 AM
#9187   Seems like we are getting something positive in AKAPAK 10/28/16 11:54:19 AM
#9186   yes i am. see board for message. matt6314 10/23/16 03:41:10 PM
#9185   Matt if you are Krazykat I sent you Abig 10/23/16 03:19:45 PM
#9184   Gosox, if I attend the only means Emerald Isle 10/21/16 08:11:43 AM
#9183   Abig, do you have a handle on some other matt6314 10/21/16 07:28:10 AM
#9182   Emerald, I forgot to ask, are you flying there gosox12 10/20/16 10:44:47 PM
#9181   Emerald, Thanks for the great news. Hope you're feeling gosox12 10/20/16 06:47:31 PM
#9180   I contacted the CEO through email and discovered Emerald Isle 10/20/16 05:29:32 PM
#9178   Yman The reaction is to the published pdf version gosox12 10/08/16 10:59:44 PM
#9177   Tomorrow tomorrow tomorrow creeps in its petty pace Abig 10/08/16 01:42:59 PM
#9176   "Did you ever get any reactions to the yman 10/08/16 01:17:28 PM
#9175   Emerald, Great to see you posting again, and especially gosox12 10/07/16 02:39:21 PM
#9174   Great news. If anyone goes, report back! Haliday 10/06/16 01:58:31 PM
#9173   Announcing... Emerald Isle 10/06/16 10:52:08 AM
#9172   I guess your question was to hard. yman 09/29/16 10:13:09 PM
#9171   Well that is the truth. 70000 shares and Haliday 09/26/16 08:35:42 PM
#9170   Please take good care. True longs are very patient. kcheung00 09/15/16 10:39:25 AM
#9169   I apologise for my absence but I've been Emerald Isle 09/14/16 10:28:30 PM
#9168   tednot, very few people know about the preliminary rckuehn 09/14/16 06:34:05 PM
PostSubject